39418 Investors following Cipla. Share this News with them.
0
Like this story, share it with millions of investors on M3
Cipla Q3 net up, guides 8-10% topline growth in FY11
Cipla's Q3 net sales were up 6.31% at Rs 1,344.2 crore versus Rs 1,264.3 crore and net profit was up 29.36% at Rs 289 crore versus Rs 223.4 crore YoY. In an interview with CNBC-TV18, Amar Lulla, CEO, Cipla spoke about the quarter gone by and the road ahead.
Cipla has declared its third quarter results for FY10. The company's Q3 net sales were up 6.31% at Rs 1,344.2 crore versus Rs 1,264.3 crore, year-on-year (YoY). Its net profit was up 29.36% at Rs 289 crore versus Rs 223.4 crore YoY. The company's trailing 12-month (TTM) EPS was at Rs 12.38 per share (Sep, 2009).
In an interview with CNBC-TV18, Amar Lulla, CEO, Cipla spoke about the quarter gone by and the road ahead.
Here is a verbatim transcript of the interview. Also watch the accompanying video.
Q: Could you take us through what kind of growth you have seen in domestic formulation and export revenue - could you give us a split between these?
A: The total income from operations has grown by about 7.1%, and the domestic has grown by 14% and the exports have grown by about 6%.
Q: How have anti retro viral drugs (ARV) sales done?
A: ARV sales we have consciously optimised by not participating in the low margin tenders. So we have tried to optimise on the margins and improved our margins. So, there has been some short fall, some reduction in the ARV business.
Q: How much has margins improved in this quarter?
A: Margins have improved to 26.2% as against 21.8% in the previous quarter.
Cipla has declared its third quarter results for FY10. The company's Q3 net sales were up 6.31% at Rs 1,344.2 crore versus Rs 1,264.3 crore, year-on-year (YoY). Its net profit was up 29.36% at Rs 289 crore versus Rs 223.4 crore YoY. The company's trailing 12-month (TTM) EPS was at Rs 12.38 per share (Sep, 2009).
